MSD and Pfizer COVID Pills Add Anaphylaxis in ADR List: Label Update

June 15, 2022
The Ministry of Health, Labor and Welfare (MHLW) on June 14 ordered label revisions for nine drugs including the addition of anaphylaxis risks for two COVID-19 pills Lagevrio (molnupiravir) and Paxlovid (nirmatrelvir/ritonavir), respectively developed by MSD and Pfizer. In the...read more